TWF2 and renal cell carcinoma: Furthermore, the TWF2 inhibitor Sal E was identified, and combination treatment with Sal E and sunitinib produced a synergistic antitumor effect in patient‐derived RCC PDX mice, outperforming sunitinib monotherapy.